Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

erability of XL019 when administered orally once daily for 21 days in 28-day cycles. Secondary objectives include evaluation of the pharmacokinetics and pharmacodynamics of XL019, and to evaluate response using the International Working Group for MF consensus response criteria.

Results To-Date

Data (unaudited) from cohort 1 (100mg), cohort 2 (200mg) and cohort 3 (300mg) were presented today and the key findings by investigators include:

-- Preliminary clinical activity observed in most subjects, including:

- Reduction in spleen size of 33 to 100% in five of six patients

evaluated

- Reduction in erythropoietin-independent colony formation of up to

39% and up to 100% in two patients evaluated

-- Relief of constitutional symptoms, including pruritus, fatigue, back

pain and abdominal fullness

-- Reduction in the number of cells with the JAK2 V617F mutation (allele

burden)

-- Correlation between XL019 exposure and decreases in phosphorylation of

STAT, a marker for JAK activity.

-- XL019 was generally well tolerated.

- Adverse events included Grade 1 nausea, headaches, equilibrium

imbalance, dizziness, chest discomfort, visual disturbances, fatigue

and hypertension.

- Grade 2 AEs of lightheadedness and decreased sensation in soles and

one serious adverse event of confusion in a patient with baseline

history of dementia were also observed.

-- No evidence of myelosuppression

The maximum tolerated dose has not been reached. The phase 1 dose escalating clinical trial continues.

About JAK2 and XL019

JAK kinases are activated by cytokines and growth factor receptors and phosphorylate members of the STAT family of inducible transcription factors. JAK2 plays a pivotal role in the cellular response to growth factors that drive blood cell expansion, including erythrop
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DUBLIN , September 22, 2014 /PRNewswire/ ... ) has announced the addition of the  ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... used to wirelessly operate electronic gadgets such ... gaming consoles from a short line-of-sight distance. ...
(Date:9/22/2014)... 22, 2014 A study on ... recently added to Transparency Market Research,s database of market ... Analysis, Size, Share & Forecast (2011 - 2017)", the ... US$ 3.9 billion in 2011, would observe growth at ... period of the report), and end-up valuing US$ 4.8 ...
(Date:9/22/2014)... Mass. , Sept. 22, 2014 Decision Resources ... pharmaceutical market is expected to be worth $2 billion (U.S. ... percent over the next five years (to 2018). This growth ... of 4.8 percent in 2013 and 4.9 percent expected over ... pharmaceutical landscape is small but highly competitive. The pharmaceutical ...
Breaking Medicine Technology:Global Remotes Market 2014-2018 2Global Remotes Market 2014-2018 3Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 2Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 3Global Magnetic Resonance Imaging (MRI) Market Worth US $4.8 Billion by 2017: Transparency Market Research 4Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
... Del., March 20, 2012 Universal Capital Management, Inc. ... to purchase ProShield™ assets, a product owned by Seitz ... expected to be structured whereby the ProShield™ assets will ... of Universal, whose management team will include John Seitz, ...
... March 20, 2012  OriGene Technologies today announced the ... and extensively validated monoclonal antibodies under the UltraMAB™ ... antibodies which are exclusively developed by OriGene for ... products available on the market that have been ...
Cached Medicine Technology:Universal Capital Management Signs Letter of Intent to Purchase ProShield™ Assets 2Universal Capital Management Signs Letter of Intent to Purchase ProShield™ Assets 3OriGene Technologies Announces the Release Specificity-Verified UltraMAB™ Antibodies 2
(Date:9/22/2014)... News) -- All sexually active women should be ... transmitted infections: chlamydia and gonorrhea, according to new ... The task force noted this recommendation ... of age and pregnant women. Most women ... As a result, many infections go undetected. If ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... that all children aged 6 months and older be vaccinated ... Pediatrics updated their influenza vaccine recommendations to advise that the ... build immunity. The AAP also wants parents of children aged ... spray vaccine instead of the flu shot if it,s readily ...
(Date:9/22/2014)... scientists have found that an anticonvulsant drug may help ... Although dozens of antibiotics target what bacteria do, their ... bacteria are created, and they found there is a ... important as there is growing concern worldwide about how ... The World Health Organization has declared that antibiotic resistance ...
(Date:9/22/2014)... 22, 2014 Quincy Bioscience, one ... States, promotes National Self-Improvement Month this ... individuals should have access to self-improvement resources, especially ... The demand for products that preserve health is ... before. For over six years, Quincy Bioscience has ...
(Date:9/22/2014)... (HealthDay News) -- Scans of young children,s brains ... This finding could potentially allow doctors to identify ... on, preliminary research suggests. "Early identification and ... as well as most neurodevelopmental disorders," the study,s ... of child and adolescent psychiatry at University of ...
Breaking Medicine News(10 mins):Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
... 5 The National Association for Sport,and Physical ... new,partnership to help to educate, challenge, and encourage ... for a healthy and fit life. As,the new ... S&S Worldwide,will assist the nonprofit education association in ...
... Recent news reports,confirm that obesity rates continued to ... be surprising to learn that there are some foods ... of the general population and 18,percent of pregnant moms ... experts, including the American Heart Association (AHA) and,American Dietetic ...
... in Her Own Fluids ... Refuses to Evacuate Her, MIAMI, Sept. 5 A lawsuit ... on the Carnival Cruise,Lines ship, the Carnival Legend, committed medical malpractice ... of,medical care. Suit was filed by John H. (Jack) Hickey who ...
... to cardiovascular disease and type II diabetes is under ... study, which follows 523 pairs of twins, is funded ... Institutes of Health. , Cardiovascular disease and type ... challenge to the United States, says Dr. Frank Treiber, ...
... (Amex: PRZ ), one of the nation,s ... services, today announced that it has,successfully closed on ... which,owns and operates an ambulatory surgery center (ASC) ... Center, located in Coral Gables, Florida.,The completed sales ...
... Product to Enhance Patient Safety, Improve Efficiency, ... a $1,billion-plus global services firm that specializes in ... today announced,that it has been awarded a $1 ... a two- hospital, 619-bed regional health system,based in ...
Cached Medicine News:Health News:National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Children's Fitness 2Health News:National Association for Sport and Physical Education Partners with S&S Worldwide to Help Improve Children's Fitness 3Health News:Eat Seafood, See Weight Loss: Recent Study Finds Another Reason to Eat Seafood for a Fit Lifestyle 2Health News:Medical Malpractice at Sea 2Health News:Environmental stress probed in cardiovascular disease, diabetes 2Health News:PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers 2Health News:PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers 3Health News:PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers 4Health News:Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility 2Health News:Keane Wins $1 Million Electronic Medical Record (EMR) Implementation at New Jersey-Based Acute Care Facility 3
... Jenner Stain is used for staining ... one of the oldest stain formulations ... results similar to that of Giemsa ... appear brighter red; basophilic granules and ...
... Our Buffered Wright-Giemsa Stain ... that contains the fixative, buffer, ... convenient staining of blood smears. ... 32-oz. bottle for ease of ...
RABIT (Rapid Automated Bacterial Impedance Technique) has been developed by Don Whitley Scientific over several years with the aid of leading product and computer design consultants....
For the quantitative determination of Albumin in serum. Endpoint procedure with Amax at 630 nm. Linearity: to 6 g/dl. Liquid ready-to-use reagent....
Medicine Products: